Items | groups | Cases (n) | Treatment time* | Repeated measures† | ||||
Baseline | 6 months | 12 months | Interaction effect, P | Time effect, P | Group effect, P | |||
Aβ40 (pg/mL) | Intervention | 105 | 27.78±20.80 | 26.88±20.81 | 28.62±20.79 | 0.468 | 0.027 | 0.480 |
Control | 105 | 33.46±24.06 | 32.43±24.00 | 33.22±23.20 | ||||
Aβ42 (pg/mL) | Intervention | 105 | 34.39±21.71 | 32.33±21.70 | 30.50±21.69 | <0.001 | <0.001 | 0.987 |
Control | 105 | 33.28±21.26 | 33.76±21.24 | 33.19±20.51 | ||||
PS1 (pg/mL) | Intervention | 105 | 48.78±44.39 | 48.89±44.39 | 48.89±44.39 | 0.951 | 0.727 | 0.272 |
Control | 105 | 44.51±37.92 | 44.63±37.92 | 44.74±37.65 | ||||
PS2 (pg/mL) | Intervention | 105 | 10.43±19.02 | 10.57±19.02 | 10.69±19.03 | 0.142 | <0.001 | 0.133 |
Control | 105 | 11.01±17.44 | 11.17±17.44 | 11.55±17.53 | ||||
PS1mRNA | Intervention | 105 | 28.85±2.59 | 30.19±2.61 | 29.77±2.59 | 0.040 | <0.001 | 0.070 |
Control | 105 | 28.89±2.58 | 30.41±2.58 | 29.86±2.60 | ||||
PS2mRNA | Intervention | 105 | 4.00±0.43 | 4.34±0.53 | 4.17±0.53 | 0.121 | <0.001 | 0.409 |
Control | 105 | 4.18±0.39 | 4.60±0.61 | 4.34±0.38 | ||||
APP | Intervention | 105 | 44.75±39.77 | 41.69±39.73 | 39.96±39.59 | <0.001 | <0.001 | <0.001 |
Control | 105 | 44.71±33.20 | 42.56±33.20 | 45.56±33.24 | ||||
APPmRNA | Intervention | 105 | 32.59±1.53 | 30.28±1.50 | 27.96±1.54 | <0.001 | <0.001 | <0.001 |
Control | 105 | 32.41±1.41 | 31.44±1.47 | 31.55±1.38 | ||||
BACE1 (µg/mL) | Intervention | 105 | 300.83±11.96 | 298.14±11.97 | 296.23±12.01 | <0.001 | <0.001 | <0.001 |
Control | 105 | 299.94±12.05 | 297.76±12.06 | 300.62±11.84 | ||||
BACE1mRNA | Intervention | 105 | 27.59±1.29 | 25.29±1.55 | 23.48±1.91 | <0.001 | <0.001 | <0.001 |
Control | 105 | 27.24±1.32 | 26.09±1.31 | 27.82±1.27 | ||||
25-D (ng/mL) | Intervention | 105 | 18.82±2.91 | 20.90±3.12 | 22.77±3.41 | <0.001 | <0.001 | <0.001 |
Control | 105 | 19.44±2.81 | 19.18±2.81 | 19.08±2.84 | ||||
1,25-D (ng/mL) | Intervention | 105 | 30.37±2.60 | 31.79±2.57 | 33.61±2.77 | <0.001 | <0.001 | <0.001 |
Control | 105 | 30.22±2.67 | 29.01±2.67 | 30.71±2.64 |
*Presented as mean±SD.
†P value for group (intervention vs control) derived from analysis of covariance adjusted for respective baseline value and for age, gender and education.
Aβ, amyloid beta; APP, Aβ protein precursor; BACE1, β-secretase 1; 25-D, 25-hydroxy vitamin D; 1,25-D, 1,25-dihydroxy vitamin; PS, presenilin.